Stock 2181 MABPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mabpharm Limited

Equities

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:09:00 03/05/2024 BST 		5-day change 1st Jan Change
0.395 HKD 0.00% Intraday chart for Mabpharm Limited -4.82% -14.13%
03-26 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-10 Livzon Pharma Recognizes Credit, Asset Impairments MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 4,238 3,645 3,360 1,584 1,724
Enterprise Value (EV) 1 3,579 3,200 3,325 1,707 1,833
P/E ratio -19.3 x -19.7 x -11.5 x -7.52 x -8.24 x
Yield - - - - -
Capitalization / Revenue 301 x 160 x 40.5 x 28.3 x 19.8 x
EV / Revenue 254 x 140 x 40.1 x 30.5 x 21 x
EV / EBITDA -20.7 x -21.7 x -12.7 x -9.29 x -12.2 x
EV / FCF -15.6 x -19.3 x -10 x -6.94 x -23.6 x
FCF Yield -6.43% -5.17% -9.96% -14.4% -4.23%
Price to Book 4.02 x 4.13 x 5.58 x 3.95 x 8.41 x
Nbr of stocks (in thousands) 4,124,080 4,124,080 4,124,080 4,124,080 4,124,080
Reference price 2 1.028 0.8837 0.8148 0.3842 0.4181
Announcement Date 24/04/20 21/04/21 21/04/22 20/04/23 18/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 23.93 14.07 22.78 82.88 55.92 87.16
EBITDA 1 -108 -172.7 -147.2 -262.8 -183.7 -150.1
EBIT 1 -119.7 -187.2 -163.4 -297.5 -226.3 -202
Operating Margin -500.23% -1,330.07% -717.48% -358.97% -404.61% -231.74%
Earnings before Tax (EBT) 1 -152.6 -202.5 -184.6 -291.7 -210.8 -209.4
Net income 1 -124.9 -202.5 -184.6 -291.7 -210.8 -209.4
Net margin -521.93% -1,439.03% -810.54% -352% -377.01% -240.19%
EPS 2 -0.0600 -0.0533 -0.0448 -0.0707 -0.0511 -0.0508
Free Cash Flow 1 -92.86 -230 -165.4 -331 -245.9 -77.63
FCF margin -388.11% -1,634.43% -726.11% -399.4% -439.68% -89.07%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/05/19 24/04/20 21/04/21 21/04/22 20/04/23 18/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 123 109
Net Cash position 1 80.1 660 444 35.1 - -
Leverage (Debt/EBITDA) - - - - -0.6682 x -0.7276 x
Free Cash Flow 1 -92.9 -230 -165 -331 -246 -77.6
ROE (net income / shareholders' equity) -74.3% -31.1% -19.1% -39.3% -42% -69.1%
ROA (Net income/ Total Assets) -19.6% -12.5% -7.98% -18% -15.6% -12.9%
Assets 1 636.3 1,618 2,313 1,618 1,355 1,619
Book Value Per Share 2 0.0700 0.2600 0.2100 0.1500 0.1000 0.0500
Cash Flow per Share 2 0.0600 0.1400 0.1200 0.0200 0.0100 0.0400
Capex 1 52.8 114 197 149 125 19
Capex / Sales 220.62% 806.94% 865.9% 179.37% 223.77% 21.85%
Announcement Date 17/05/19 24/04/20 21/04/21 21/04/22 20/04/23 18/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MABPHARM LIMITED Stock Mabpharm Limited
-14.13% 208M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 101B
ARGENX SE Stock argenx SE
+4.40% 23.07B
BIONTECH SE Stock BioNTech SE
-12.15% 22.23B
GENMAB A/S Stock Genmab A/S
-4.36% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2181 Stock
  4. Financials Mabpharm Limited